Improving nerve health to reduce pain from chemotherapy
Targeting Schwann cell dysfunction and repair signaling in chemotherapy induced painful peripheral neuropathy
['FUNDING_R01'] · NEW YORK UNIVERSITY · NIH-10856514
This study is looking at how to help people with painful nerve damage from chemotherapy by focusing on special cells that support nerve health, with the hope of finding new ways to ease their pain while still allowing them to receive their cancer treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10856514 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding and addressing the painful nerve damage caused by chemotherapy, known as chemotherapy-induced painful peripheral neuropathy (CIPPN). It investigates the role of Schwann cells, which are crucial for nerve function, and how their dysfunction contributes to pain. The study aims to enhance the survival and function of these cells through specific signaling pathways, potentially leading to new treatments that alleviate pain without requiring a reduction in chemotherapy. By targeting the underlying mechanisms of nerve damage, the research seeks to improve the quality of life for patients undergoing cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients experiencing painful peripheral neuropathy as a side effect of chemotherapy.
Not a fit: Patients who are not undergoing chemotherapy or do not experience peripheral neuropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that reduce pain and improve the quality of life for cancer patients receiving chemotherapy.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for nerve repair and pain relief, indicating potential for success in this approach.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YE, YI — NEW YORK UNIVERSITY
- Study coordinator: YE, YI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.